Alzheimer disease

1,634 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies (2024, background): “Currently, antibodies like aducanumab ( 1 ), lecanemab ( 2 ), and donanemab ( 10 ) show their promise in proving A β as a signi ﬁ cant factor in AD development.”
Aging and aging-related diseases: from molecular mechanisms to interventions and treatments (2022, background): “Additionally, the hyperphosphorylation of tau proteins leads to the formation of senile plaques, which lead to impaired memory and reduced cognitive function.(198) DNA mutations and defects in DNA repair mechanisms are important causes of AD.”
Hallmarks of neurodegenerative diseases. (2023, neutral): “…for pathological protein aggregation (1), synaptic and neuronal network dysfunction (2), aberrant proteostasis (3), cytoskeletal abnormalities (4), altered energy homeostasis (5), DNA and RNA defects (6), inﬂammation (7), and neuronal cell death (8). tetrabenazine that modulates dopaminergic…”